New Clinical Data Highlights Onera Health’s Patch-Based Home Polysomnography Solution at SLEEP 2025

4.6.2025 14:00:00 CEST | Business Wire | Press Release

Onera Health, a leader in transforming remote sleep diagnostics and monitoring, has today announced that its patient-applied patch-based home Polysomnography Solution will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2025 conference. The MedTech company will showcase this innovative solution at booth #1145 during the largest annual conference, which brings together leading experts and innovators in the field of sleep medicine. Furthermore, Onera Health will host a symposium on "Advancing Access to PSG" on Monday, June 9.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604390799/en/

A female patient is sleeping while undergoing a sleep study with Onera Health's home Polysomnography solution.

The 39th annual meeting of the Associated Professional Sleep Societies (APSS) will present the latest clinical data and insights that promise to reshape the landscape of sleep medicine. This year's conference will take place from June 8 to 11, 2025, in Seattle, Washington.

“We are excited to see our Patch-based Type II Polysomnography System highlighted in four different presentations and to be an integral part of the evolving field of sleep medicine by advancing access to the gold standard of PSG sleep testing,” states Ruben de Francisco, Founder and CEO of Onera Health.

The clinical utility of the Onera home PSG system will be presented in four poster presentations. Details of the presentations are as follows:

Title: Assessment of Disease Burden in PAP-Intolerant OSA Patients Using Home Polysomnography: A Pilot Study
Authors: Heiser C et al.
Poster Board Number: #219
Poster Presentation Date and Time: June 9, 2025, 10:00 - 11:45 am
Abstract ID: 661

Title: Signal Quality and Recording Characteristics of Patient-Applied Home Polysomnography: A Real-World Analysis Across US and European Settings
Authors: Dimitrov T et al.
Poster Board Number: #543
Poster Presentation Date and Time: June 10, 2025, 11:00 - 11:45 am
Abstract ID: 1666

Title: Validation of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #319
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 677

Title: Patient Perception of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #320
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 678

Additional presentations by experts from leading institutions will feature validation results, insights from real-world implementation, and the clinical implications of home PSG testing during a symposium titled "Expanding Access, Enhancing Outcomes: The Future of Sleep Diagnostics with Home Polysomnography," which will be hosted by Onera Health on June 9.

“Home polysomnography addresses significant challenges, including the shortage of in-laboratory beds, technicians, and sleep physicians. This shortage has led to escalating costs and an increasing unmet clinical demand, with many patients suffering from sleep disorders remaining undiagnosed. This symposium aims to provide valuable insights into how hPSG can enhance patient care pathways and is already beginning to reshape the landscape of sleep healthcare by broadening access to gold standard PSG testing. I am confident that it will foster engaging discussions with esteemed panelists regarding the emerging opportunities for remote sleep diagnostics and care,” explains Ruben de Francisco.

Attendees can anticipate the following presentations:

David P. White, MD, part-time Professor of Medicine at Harvard Medical School – "The Perfect Storm: Why Sleep Medicine Needs to Transform Now"
Thomas Penzel, PhD, Charité University Hospital Berlin – "Home Polysomnography Comes of Age: Validation Study Results"
Anupamjeet Kaur Sekhon, MD, Kaiser Permanente Fontana Medical Center– "From Lab to Home: Implementing Home Sleep Testing at Scale"

About Onera Health

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the United States. For further information, please visit onerahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604390799/en/

Contacts

Swea Ann Hagenhoff
E: media@onerahealth.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press Release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press Release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press Release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press Release

ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom